Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.
A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.
Division of Clinical Sciences, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK, dalgleis@sgul.ac.uk.
Angus
A
Dalgleish
Peter
P
Featherstone
Viatcheslav
V
Vlassov
Moshe
M
Rogosnitzky
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007610:Kallikreins / Q000097:blood; D008206:Lymphatic Diseases / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen